Search


 
Results 11 - 20 of about 124 for "From ACP Journal Club".

Exenatide did not reduce major cardiovascular outcomes in ...

While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high ...

September 8, 2017 | ACP Diabetes Monthly

... From ACP Journal Club. In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years. ...

In type 1 diabetes, education with either insulin pumps or daily ...

The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching ...

Review: In diabetes, intensive and standard glycemic control ...

The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease ...

February 9, 2018 | ACP Diabetes Monthly

... guidelines. From ACP Journal Club. Review compares effectiveness, cost, and safety of second-line drugs for diabetes. The ...

February 12, 2016 | ACP Diabetes Monthly

... From ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years. ...

In type 2 diabetes with CVD and kidney disease, empagliflozin ...

If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for ...

Safety of dipeptidyl peptidase-4 inhibitors analyzed in 2 ...

A meta-analysis of dipeptidyl peptidase-4 inhibitors showed no increase in pancreatic adverse events, while a trial of saxagliptin found no effect on the ...

May 11, 2018 | ACP Diabetes Monthly

... From ACP Journal Club. In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER. ...

In type 2 diabetes, weekly semaglutide reduced HbA1c and ...

Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal ...

Result Page: < Previous  1 2 3 4 5 6  Next >